CAH Q1 Earnings & Revenues Beat Estimates on Pharma Strength

Cardinal Health’s fiscal Q1 2027 adjusted EPS rose 28% year over year to $3.26, beating consensus by 11.6%, while revenue increased 5% to $67.51 billion, 0.8% above estimates. The company raised FY27 adjusted EPS guidance to $12.80-$13 from $12.40-$12.60, implying 17-19% growth; Pharmaceutical and Specialty Solutions segment profit rose 17% to $783 million. Shares gained 3.5% in pre-market trading; Cardinal Health also reported $625 million in shareholder returns, including $500 million in repurchases and $125 million in dividends.

Analysis

CAH’s key signal is improving earnings mix, not headline revenue growth: incremental profit in the core distribution business and faster-growing higher-margin platforms can support earnings even if drug-volume growth remains modest. But the EPS beat is not wholly repeatable—share-count reduction and a lower tax rate helped—so track segment profit and operating cash conversion rather than extrapolating EPS growth. The 1–3 month test is whether the raised segment outlook converts into reported profit, particularly in specialty/generics and the “Other” businesses. Over 6–18 months, acquisitions and investment in specialty, nuclear and logistics could deepen the mix shift, but integration and execution risk rise alongside it.

The CVS renewal intent reduces near-term customer-retention uncertainty for CAH, but it is not a disclosed final contract or evidence of improved economics; CVS retains meaningful negotiating leverage. The planned AdaptHealth diabetes-business acquisition merits monitoring for closing and integration details, not an assumed benefit to either company absent terms. A contrarian risk: investors may capitalize the full EPS increase as structural despite tax and repurchase contributions, while overlooking weak medical-distribution profitability. The thesis weakens if pharma segment profit growth falls short of its raised outlook, Other profit momentum fades, or cash conversion deteriorates.

Key Decisions for Investors

• CAH: constructive, but do not chase the immediate earnings reaction. Consider initiating or adding on post-event consolidation; underwrite on segment profit growth and cash generation, not adjusted EPS alone. Reassess if Pharmaceutical and Specialty Solutions misses its 10–12% profit-growth outlook or Other segment profit growth falls below guidance.
• CVS: treat the renewal letter as reduced retention risk for CAH, not a confirmed margin catalyst for CVS. Avoid a directional trade until final terms clarify duration, economics and any operational commitments.
• Watch AHCO into the expected Q3 FY27 close of the diabetes-business sale to Cardinal Health. Do not infer proceeds, earnings impact or balance-sheet benefit without transaction terms; verify closing, use of proceeds and any retained obligations.